Vol.

No.

April 24, 2020Apr 24, 2020

Free

DOWNLOAD THE PDF

Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19 Phase III results for remdesivir expected within weeks

Cover Story

COVID-19 & Cancer Free

Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19

Phase III results for remdesivir expected within weeks

By Matthew Bin Han Ong

Experts in infectious diseases and investors on Wall Street are honing in on two potential treatments for COVID-19: interleukin inhibitors and remdesivir.

Conversation with The Cancer Letter COVID-19 & Cancer Free

Berry: “Designing clinical trials doesn't have high priority when there's no pandemic. And then, when there's a pandemic, there's panic”

By Matthew Bin Han Ong

COVID-19 & Cancer Free Guest Editorial

When disparities widen: COVID-19 in minority patients with cancer

By Coral Olazagasti and Narjust Florez

COVID-19 & Cancer Free Guest Editorial

COVID-Lung Cancer Consortium:
An example of how the lung cancer community came together in a challenging time

By Fred R. Hirsch, Paul A. Bunn Jr and John D. Minna

Conversation with The Cancer Letter COVID-19 & Cancer Free

Feist-Weiller mammography vans repurposed to screen for COVID-19 in northwest Louisiana

By Alexandria Carolan

Conversation with The Cancer Letter COVID-19 & Cancer Free

Tulane Cancer Center chips away at the “digital divide” that keeps the underserved from benefiting from telemedicine

By Alexandria Carolan

Conversation with The Cancer Letter COVID-19 & Cancer Free

As COVID-19 peaks in San Antonio, Ruben Mesa predicts gradual reopening

By Paul Goldberg

COVID-19 Updates

FDA issues advisory on off-label use of hydroxychloroquine and chloroquine

AACI's CRI annual meeting goes virtual

Reagan-Udall Foundation and Friends of Cancer Research form COVID-19 Evidence Accelerator focused on RWE

Western NY researchers study COVID-19 using NGS to identify immune response biomarkers

Invitae develops tools to support telemedicine

Kennedy, former FDA commissioner and Stanford president, dies of COVID-19

FAQs and Guidances

In Brief

ASCO announces 2020 awards

Serody and Basch named to leadership roles at UNC

Poynter, Harki appointed to leadership team at Masonic Cancer Center

American Heart Association grants $17 million for studies on health impact of e-cigarettes and nicotine on youth

Clinical Roundup

Phase III CheckMate-743 study of Opdivo and Yervoy meets primary OS endpoint in mesothelioma

Phase III CheckMate -9ER meets primary PFS endpoint in RCC

New targeted agent produces responses in trial with patients with uterine serous carcinoma

RVD Therapy shows substantial benefit in large myeloma study

Cue Biopharma and Merck to evaluate CUE-101 + Keytruda in head and neck indication

Drugs & Targets

FDA approves Tukysa in breast cancer indication

FDA grants accelerated approval for Trodelvy in previously-treated metastatic TNBC

FDA approves first targeted treatment for patients with cholangiocarcinoma

FDA approves Imbruvica in CLL/SLL indication

FDA approves Keytruda companion diagnostic

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 43 - November 21, 2025

Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19

Berry: “Designing clinical trials doesn't have high priority when there's no pandemic. And then, when there's a pandemic, there's panic”

When disparities widen: COVID-19 in minority patients with cancer

COVID-Lung Cancer Consortium:
An example of how the lung cancer community came together in a challenging time

Feist-Weiller mammography vans repurposed to screen for COVID-19 in northwest Louisiana

Tulane Cancer Center chips away at the “digital divide” that keeps the underserved from benefiting from telemedicine

As COVID-19 peaks in San Antonio, Ruben Mesa predicts gradual reopening

COVID-19 Updates

FDA issues advisory on off-label use of hydroxychloroquine and chloroquine

AACI's CRI annual meeting goes virtual

Reagan-Udall Foundation and Friends of Cancer Research form COVID-19 Evidence Accelerator focused on RWE

Western NY researchers study COVID-19 using NGS to identify immune response biomarkers

Invitae develops tools to support telemedicine

Kennedy, former FDA commissioner and Stanford president, dies of COVID-19

FAQs and Guidances

In Brief

ASCO announces 2020 awards

Serody and Basch named to leadership roles at UNC

Poynter, Harki appointed to leadership team at Masonic Cancer Center

American Heart Association grants $17 million for studies on health impact of e-cigarettes and nicotine on youth

Clinical Roundup

Phase III CheckMate-743 study of Opdivo and Yervoy meets primary OS endpoint in mesothelioma

Phase III CheckMate -9ER meets primary PFS endpoint in RCC

New targeted agent produces responses in trial with patients with uterine serous carcinoma

RVD Therapy shows substantial benefit in large myeloma study

Cue Biopharma and Merck to evaluate CUE-101 + Keytruda in head and neck indication

Drugs & Targets

FDA approves Tukysa in breast cancer indication

FDA grants accelerated approval for Trodelvy in previously-treated metastatic TNBC

FDA approves first targeted treatment for patients with cholangiocarcinoma

FDA approves Imbruvica in CLL/SLL indication

FDA approves Keytruda companion diagnostic

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login